JP2023507387A - インテグリン阻害剤を使用する肝疾患の治療の組み合わせ - Google Patents

インテグリン阻害剤を使用する肝疾患の治療の組み合わせ Download PDF

Info

Publication number
JP2023507387A
JP2023507387A JP2022537270A JP2022537270A JP2023507387A JP 2023507387 A JP2023507387 A JP 2023507387A JP 2022537270 A JP2022537270 A JP 2022537270A JP 2022537270 A JP2022537270 A JP 2022537270A JP 2023507387 A JP2023507387 A JP 2023507387A
Authority
JP
Japan
Prior art keywords
liver
tropifexor
compound
pharmaceutical combination
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507387A5 (enExample
Inventor
アンダーソン，クレイグ
バイリー，クリストファー
ボーズ，アヴィラップ
チャ，ジェイコブ
クーパー，ニコル
フィンケルステイン，ダレン
グリーンバーム，リンダ
フル，ヨハネス
カークランド，スーザン
レフテリス，カテリーナ
レイリー，モーリーン
タルサ，ピーター
ウコマドゥ，チンウェイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of JP2023507387A publication Critical patent/JP2023507387A/ja
Publication of JP2023507387A5 publication Critical patent/JP2023507387A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022537270A 2019-12-20 2020-12-18 インテグリン阻害剤を使用する肝疾患の治療の組み合わせ Pending JP2023507387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951615P 2019-12-20 2019-12-20
US62/951,615 2019-12-20
PCT/US2020/066079 WO2021127483A1 (en) 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors

Publications (2)

Publication Number Publication Date
JP2023507387A true JP2023507387A (ja) 2023-02-22
JP2023507387A5 JP2023507387A5 (enExample) 2023-10-26

Family

ID=74186956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537270A Pending JP2023507387A (ja) 2019-12-20 2020-12-18 インテグリン阻害剤を使用する肝疾患の治療の組み合わせ

Country Status (11)

Country Link
US (1) US20230055657A1 (enExample)
EP (1) EP4076455A1 (enExample)
JP (1) JP2023507387A (enExample)
KR (1) KR20220121838A (enExample)
CN (1) CN114929219A (enExample)
AR (1) AR120859A1 (enExample)
AU (1) AU2020405182B2 (enExample)
CA (1) CA3165000A1 (enExample)
IL (1) IL293895A (enExample)
TW (1) TW202135812A (enExample)
WO (1) WO2021127483A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220206A1 (en) * 2019-05-20 2022-07-14 Mayo Foundation For Medical Education And Research Treating chronic liver disease
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180093984A1 (en) * 2016-09-07 2018-04-05 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
RU2019110780A (ru) * 2016-09-14 2020-10-15 Новартис Аг Комбинация агонистов fxr
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN118852054A (zh) * 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180093984A1 (en) * 2016-09-07 2018-04-05 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cho", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6024043295, 2017, pages 9960 - 9973, ISSN: 0005577343 *

Also Published As

Publication number Publication date
AU2020405182B2 (en) 2024-03-14
EP4076455A1 (en) 2022-10-26
CA3165000A1 (en) 2021-06-24
AU2020405182A1 (en) 2022-07-07
IL293895A (en) 2022-08-01
KR20220121838A (ko) 2022-09-01
US20230055657A1 (en) 2023-02-23
CN114929219A (zh) 2022-08-19
TW202135812A (zh) 2021-10-01
AR120859A1 (es) 2022-03-23
WO2021127483A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US20220265619A1 (en) Combination treatment of liver diseases using fxr agonists
EP4646220A1 (en) Combination therapy of apelin receptor agonist and glp-1 receptor agonist for treating a disease or condition associated with weight gain
US20210283105A1 (en) Novel regimes of fxr agonists
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
JP2019530696A (ja) 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物
US20230060422A1 (en) Combination treatment of liver diseases using integrin inhibitors
US20200276178A1 (en) Combinations comprising fxr agonists
JP2023507387A (ja) インテグリン阻害剤を使用する肝疾患の治療の組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422